Twitxy Saved

J. Keith Joung

@JKeithJoung

Lead Translator @arenabioworks, formerly Professor of Pathology (on leave, 2023-2025) @HarvardMed, #geneediting, #CRISPR; views expressed are my own
Boston, MA linkedin.com/in/keith-joung… Joined May 2019
539 Following 4.5K Followers 423 Posts

Latest posts 5

J. Keith Joung @JKeithJoung
Thrilled to see Arena welcome @harveyjberger as Chairman and CEO. With our founder, @SchreiberStuart, continuing as CSO, I’m excited to be heading up discovery research and our promising early-stage programs.
Arena BioWorks @arenabioworks Sep 8, 2025
Arena welcomes @HarveyJBerger as Chairman & CEO, joining Founder & CSO @schreiberstuart to advance our mission. By incorporating causal mechanisms of human disease, we are building a new model for discovering and developing breakthrough medicines. bit.ly/4822J5B
View quoted post on X
1 replies 1 reposts 7 likes 2.3K views View on X
J. Keith Joung @JKeithJoung
Very cool new work from the labs of @SchmidtsAndrea and @grunewaju using AI to rapidly engineer new binders for CAR-T cells: biorxiv.org/content/10.110… #GenerativeAI #CARTcell
www.biorxiv.org Engineering de novo binder CAR-T cell therapies with generative AI Chimeric antigen receptor T cell (CAR-T) therapies have revolutionized cancer treatment, with six CAR-T products currently in clinical use[1][1]–[4][2]. Despite their success, high resistance rates...
Andrea Schmidts @SchmidtsAndrea Nov 26, 2024
Cancer escapes immunotherapies by mutating its surface. This means even groundbreaking #CARTCell therapies fail too often because of cancer resistance. But what if we could use #GenerativeAI to design CAR-T with de novo binders faster and smarter, targeting even resistant tumors? In the first preprint from my & @grunewaju's labs @TU_Muenchen, we show how this could work for new #celltherapies and #genetherapies. (1) 🧵biorxiv.org/content/10.110…
View quoted post on X
4 replies 5 reposts 30 likes 2.6K views View on X
J. Keith Joung @JKeithJoung
Delighted to share this news. Combining SeQureDx’s & @idtdna's innovative technologies will enhance precision and safety in gene editing, bringing transformative solutions to researchers and patients worldwide. #CRISPR #GeneEditing
Integrated DNA Technologies Verified account @idtdna Jul 15, 2024
💥Big news!💥

We’re partnering with SeQure Dx to support cell and #genetherapy developers through all phases of their #CRISPR-based therapeutic programs. Read more about this exciting development here: idtb.io/2ta4gg

#CRISPRanalysis #CRISPRtherapeutics
View quoted post on X
0 replies 4 reposts 21 likes 3.1K views View on X
J. Keith Joung @JKeithJoung
Great fun & very exciting to finally unveil @nvelop_tx's DLVR-M platform with co-inventor Peter Cabeceiras at #ASGCT2024 in Baltimore last week. DLVR-M is based on work originally done by Peter during his Ph.D. work in my lab at the @MGH_RI. linkedin.com/posts/nveloptx…
www.linkedin.com #asgct2024 | Nvelop Therapeutics Great to have participated at the 27th Annual American Society of Gene & Cell Therapy (ASGCT) meeting and share the first preclinical data from our novel DLVR-M delivery platform.   Thank you, Peter...
4 replies 4 reposts 23 likes 2.5K views View on X
J. Keith Joung @JKeithJoung
As #ASGCT2024 nears its end, I'm excited to attend Poster Session 3 this afternoon. I also look forward to answering questions and talking about the GUIDE-seq & ONE-seq assays originally developed in my lab @MGH_RI (details below). linkedin.com/posts/sequre-d…
www.linkedin.com #asgct2024 | SeQure DX Our final #ASGCT2024 poster presentation is taking place this evening from 5:30 to 7 pm. Keith Joung the co-inventor of GUIDE-seq and ONE-seq and our scientific co-founder will be joining us at our...